The Invisible Epidemic: Neglected Chronic Disease Management During COVID-19
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
P revention, early detection, and ongoing patient monitoring are hallmarks of essential primary care. 2 During the COVID-19 pandemic, patients and PCPs have appropriately canceled or postponed many outpatient visits and converted others to telemedicine due to shortages of healthcare resources or the risk of infection. The USPSTF recommends screening adults for diabetes and dyslipidemia; diagnosed patients require ongoing treatment and monitoring. Our objective was to evaluate the impact of the COVID-19 pandemic on the rate of performance of screening and prevention services and assess the implications of these changes. As part of an ongoing research project monitoring patients newly started on medications in primary care, data were collected before and during the pandemic. To examine the impact of COVID-19, we obtained IRB approval to expand the study to include two large healthcare institutions during the period of February–May 2020. We also looked at changes in outpatient LDL cholesterol and HbA1c testing and initiation of statin and metformin therapy, as representative initial steps that providers might take to reduce the risk of cardiovascular events or manage diabetes. During February–March, rates of testing fell by 81– 90% and new medication therapy by 52–60% (P < 0.001 for all before and after comparisons using a t test). The rates started a modest rebound in early April, more pronounced at site 2 (Fig. 1). The dramatic decline in preventive screening and monitoring for the 2 chronic diseases which occurred in February and March is concerning. It adds to a growing narrative about care delays during the COVID-19 pandemic, including acute care for patients with stroke or myocardial infarction, as well as cancer treatment and childhood vaccinations. 5 Preventive services, routine monitoring, and treatment of lipid disorders and diabetes, though likely safer to temporarily defer during the current COVID-19 crisis than these other acute services, have been shown to be lifesaving. The cumulative risk over time may be significant. While it is unlikely that patients will suddenly die as a result of these delays, a number of patients who might have otherwise been detected and treated earlier will likely present to the ED with new or dangerously out-of-control diabetes. However, the real concern is the longer-term population-based consequences of failure to detect, prevent, and treat conditions, such as diabetes and cardiac risks from hyperlipemia. A mild rebounding effect that started demonstrating in early April does not seem to be sufficiently strong to catch up on the backlog of tests accumulated during the two slow months. To mitigate longer-term consequences, healthcare providers should take several steps, including resuming primary care services as soon as it is safe and practical, identifying population-based registries of patients with gaps in care, specifically targeting the gaps resulting from COVID-19-related deferrals, and creating options and ensuring insurance coverage for nontraditional lab collection options, such as neighborhood pharmacy, other specimen collection centers, or home testing kits. Practices need to emphasize the importance of ongoing prevention screening, monitoring, and treatment to patients who may continue to be fearful about returning to healthcare facilities. In the longer term, such strategies could be used to expand the capacity for screening or prevention to levels greater than during the pre-COVID-19 baseline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary Care: Is There Enough Time for Prevention?
Yarnall, K. S. H., Pollak, K. I., Østbye, T., Krause, K. M., & Michener, J. L. (2003) · American Journal of Public Health · doi:10.2105/ajph.93.4.635 · Cited by 1,641
Cited by
Zhou, B., Perel, P., Mensah, G. A., & Ezzati, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00559-8 · Cited by 1,521
Eruchalu, C. N., Pichardo, M. S., Bharadwaj, M., Rodriguez, C. B., Rodriguez, J. A., Bergmark, R. W., Bates, D. W., & Ortega, G. (2021) · Journal of Urban Health · doi:10.1007/s11524-020-00508-9 · Cited by 245
The Use and Promise of Conversational Agents in Digital Health
Dingler, T., Kwasnicka, D., Wei, J., Gong, E., & Oldenburg, B. (2021) · Yearbook of Medical Informatics · doi:10.1055/s-0041-1726510 · Cited by 81
Distinguishing features in the assessment of mHealth apps
Tarricone, R., Petracca, F., Ciani, O., & Cucciniello, M. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1891883 · Cited by 62
“No matter how we reach this new equilibrium, it is fundamental that none is left behind by the digital revolution as it happened with analog systems for several youth and adult chronic patients during the COVID-19 pandemic [48–50].”
BackgroundAcute surgical abdomen during the COVID 19 pandemic: Clinical and therapeutic challenges
Serban, D., Socea, B., Badiu, C., Tudor, C., Balasescu, S., Dumitrescu, D., Trotea, A., Spataru, R., Vancea, G., Dascalu, A., et al. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9950 · Cited by 39
Metadata
- Authors
- Wright, A., Salazar, A., Mirica, M., Volk, L. A., & Schiff, G. D.
- Venue
- Journal of General Internal Medicine
- Published
- 2020-07-14
- Volume
- 35
- Issue
- 9
- Pages
- 2816-2817
- ISSN
- 0884-8734 (ISSN-L)
- 1525-1497
- OpenAlex
- W3042854882
- Cited by
- 189
- References
- 1
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Invisible Epidemic: Neglected Chronic Disease Management During COVID-19. https://app.cochat.ai/papers/10.1007/s11606-020-06025-4
- The paper
- Wright, A., Salazar, A., Mirica, M., Volk, L. A., & Schiff, G. D. (2020). The Invisible Epidemic: Neglected Chronic Disease Management During COVID-19. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-020-06025-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.